» Articles » PMID: 25187816

Graft Versus Host Disease Following Liver Transplantation: A Case Report

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2014 Sep 5
PMID 25187816
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Graft versus host disease (GVHD) is an uncommon complication following liver transplantation. In the present case report, a 53-year-old male hepatitis B virus carrier was diagnosed with primary liver cancer with post-hepatitis cirrhosis. Preoperative cytomegalovirus (CMV), Epstein-Barr virus, coxsackievirus, herpes simplex virus and autoimmune antibody series were negative. Preoperative human leukocyte antigen type was also negative. Following classic orthotropic liver transplantation, postoperative treatment included immunosuppression therapy, infection protection, anti-human immunodeficiency virus therapy and CMV infection protection therapy. Chemotherapy was initiated at day 16 following surgery. At day 26 following the transplantation, the patient developed a fever of unknown cause, and a scattered red rash was observed behind the left ear and on the neck. The patient presented with a fever of unknown cause, rash, symptoms of the digestive tract, leukocytopenia and pancytopenia. A diagnosis of GVHD was confirmed following a skin biopsy. Symptomatic therapies, including antivirals, anti-anaphylaxis drugs and steroids were administered. However, the patient succumbed to infection, acute respiratory distress syndrome and multiple organ failure at day 46 following surgery. Therefore, an effective therapeutic strategy for the treatment of GVHD following liver transplantation is yet to be established, and further research is required prior to such a regimen being developed.

Citing Articles

Graft versus host disease after liver transplantation following radiotherapy for the treatment of hepatocellular carcinoma: A case report and literature review.

Chen Z, Han C, Wang X, He Y, Liang T, Mo S SAGE Open Med Case Rep. 2022; 10:2050313X221101747.

PMID: 35646373 PMC: 9136437. DOI: 10.1177/2050313X221101747.


Dermatologic manifestations of solid organ transplantation-associated graft-versus-host disease: A systematic review.

Kim G, Schmelkin L, Davis M, El-Azhary R, Farrell A, Meves A J Am Acad Dermatol. 2017; 78(6):1097-1101.e1.

PMID: 29288097 PMC: 6167008. DOI: 10.1016/j.jaad.2017.12.050.


Immunological basis for treatment of graft versus host disease after liver transplant.

Rai V, Dietz N, Agrawal D Expert Rev Clin Immunol. 2016; 12(5):583-93.

PMID: 26795873 PMC: 4955803. DOI: 10.1586/1744666X.2016.1145056.

References
1.
Thin L, MacQuillan G, Adams L, Garas G, Seow C, Cannell P . Acute graft-versus-host disease after liver transplant: novel use of etanercept and the role of tumor necrosis factor alpha inhibitors. Liver Transpl. 2009; 15(4):421-6. DOI: 10.1002/lt.21704. View

2.
Foley J, Jung U, Miera A, Borenstein T, Mariotti J, Eckhaus M . Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol. 2005; 175(9):5732-43. DOI: 10.4049/jimmunol.175.9.5732. View

3.
Stewart B, Storer B, Storek J, Deeg H, Storb R, Hansen J . Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004; 104(12):3501-6. DOI: 10.1182/blood-2004-01-0200. View

4.
Wilson J, Cullup H, Lourie R, Sheng Y, Palkova A, Radford K . Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med. 2009; 206(2):387-98. PMC: 2646577. DOI: 10.1084/jem.20070723. View

5.
Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View